ERBB2 and invasive breast carcinoma: The study evaluated a patient cohort with early‐stage estrogen receptor positive, HER2‐negative invasive breast cancer who had Oncotype DX Breast Recurrence Score® analysis and genetic testing for hereditary breast and ovarian cancer syndrome.